Last reviewed · How we verify

Wenhu Liu — Portfolio Competitive Intelligence Brief

Wenhu Liu pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vitamin D2 Vitamin D2 marketed Provitamin D2 Compound [EPC]

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Esjay Pharma · 1 shared drug class
  2. University of Texas Southwestern Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Wenhu Liu:

Cite this brief

Drug Landscape (2026). Wenhu Liu — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wenhu-liu. Accessed 2026-05-16.

Related